6533b852fe1ef96bd12aaed5

RESEARCH PRODUCT

Does plasma endothelin during thrombolysis depend on infarct size? A pilot study

Giuseppe LicataPietro Di PasqualeFernanda PipitoneSalvatore PaternaVincenzo BuccaGaspare ParrinelloGiuseppe Tricoli

subject

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionInfarctionPilot ProjectsInternal medicinemedicineHumansThrombolytic TherapyPharmacology (medical)cardiovascular diseasesMyocardial infarctionAgedPharmacologybusiness.industryEndothelinsGeneral MedicineCoronary ischemiaThrombolysisPlasma levelsMiddle Agedmedicine.diseaseInfarct sizeEndothelin 1Tissue Plasminogen Activatorcardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEndothelin receptor

description

Dear Sir, Endothelin is a recently discovered endotheliumderived vasoconstrictive peptide [1]. Endothelin's actions are altered in various models of cardiac injury [2]. Furthermore, it has been shown that endothelin is increased during reperfusion [2]. Studies have shown a significant increase in endothelin-1 (ET-1) in the early phases of acute myocardial infarction (AMI) and percutaneous transluminal coronary angioplasty (PTCA) [3-8]. In addition, a significant inverse relation between ventricular function and plasma ET-1 has been shown [6]. These data suggest that ET-1 may provide a marker of endothelial injury in the early phases of coronary ischemia or may even contribute to alterations in AMI [6-8]. The experimental results of Watanabe et al. suggest that increases in the ET-1 concentration may be directly related to infarct size [9]. In order to evaluate the relation between ET-1 plasma levels and localization of myocardial infarction, we carried out a clinical study on suspected AMI. The secondary purpose was to check the effects of thrombolysis on ET-1 levels in patients

yearjournalcountryeditionlanguage
1995-12-01Cardiovascular Drugs and Therapy
https://doi.org/10.1007/bf00879880